Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07AKD
|
|||
| Former ID |
DIB013183
|
|||
| Drug Name |
TOL-101
|
|||
| Synonyms |
MAb (transplant rejection), Tolera Therapeutics; Monoclonal antibody (transplant rejection), Tolera Therapeutics; Anti-TCR alpha/beta antibody (transplant rejection/type 1 diabetes/multiple sclerosis), Tolera
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 1/2 | [1] | |
| Company |
Tolera Therapeutics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell receptor (TCR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01154387) Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection. U.S. National Institutes of Health. | |||
| REF 2 | First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.